Does the media prefer RVMD or RDY?

In the previous week, Revolution Medicines had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Revolution Medicines and 2 mentions for Dr. Reddy's Laboratories. Revolution Medicines' average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDY or ONC?

BeOne Medicines has a consensus target price of $390.00, suggesting a potential upside of 31.03%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93

Does the media favor RDY or ONC?

In the previous week, BeOne Medicines had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for BeOne Medicines and 2 mentions for Dr. Reddy's Laboratories. BeOne Medicines' average media sentiment score of 0.27 beat Dr. Reddy's Laboratories' score of -0.23 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RDY or MRNA?

Moderna has a consensus target price of $37.13, indicating a potential downside of 53.44%. Given Moderna's stronger consensus rating and higher possible upside, analysts clearly believe Moderna is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Moderna 5 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.83

Does the media favor RDY or MRNA?

In the previous week, Moderna had 17 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 19 mentions for Moderna and 2 mentions for Dr. Reddy's Laboratories. Moderna's average media sentiment score of 0.66 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 5 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ROIV or RDY?

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential downside of 4.38%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to ROIV or RDY?

In the previous week, Roivant Sciences had 19 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 21 mentions for Roivant Sciences and 2 mentions for Dr. Reddy's Laboratories. Roivant Sciences' average media sentiment score of 0.74 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 12 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Dr. Reddy's Laboratories (RDY) Competitors

$14.39 +0.40 (+2.84%)

Closing price 03:59 PM Eastern

Extended Trading

$14.51 +0.12 (+0.82%)

As of 04:56 PM Eastern

Compare

RDY vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? MarketBeat compares Dr. Reddy's Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Reddy's Laboratories include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Revolution Medicines had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Revolution Medicines and 2 mentions for Dr. Reddy's Laboratories. Revolution Medicines' average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Revolution Medicines' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Revolution Medicines presently has a consensus target price of $135.39, suggesting a potential downside of 28.46%. Given Revolution Medicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Revolution Medicines is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81

Summary

Revolution Medicines beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.9%. Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend.

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 8 mentions for Teva Pharmaceutical Industries and 2 mentions for Dr. Reddy's Laboratories. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, suggesting a potential upside of 20.91%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Teva Pharmaceutical Industries has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.29	$1.41B	$1.33	25.98
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81

Summary

Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 13 of the 18 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Dr. Reddy's Laboratories (NYSE:RDY) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to BeOne Medicines' net margin of 8.94%. Dr. Reddy's Laboratories' return on equity of 12.34% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
BeOne Medicines	8.94%	12.06%	6.69%

Dr. Reddy's Laboratories has higher earnings, but lower revenue than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81
BeOne Medicines	$5.34B	6.11	$286.93M	$4.47	66.59

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

BeOne Medicines has a consensus target price of $390.00, suggesting a potential upside of 31.03%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, BeOne Medicines had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for BeOne Medicines and 2 mentions for Dr. Reddy's Laboratories. BeOne Medicines' average media sentiment score of 0.27 beat Dr. Reddy's Laboratories' score of -0.23 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Moderna?

Dr. Reddy's Laboratories (NYSE:RDY) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

In the previous week, Moderna had 17 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 19 mentions for Moderna and 2 mentions for Dr. Reddy's Laboratories. Moderna's average media sentiment score of 0.66 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	5 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a consensus target price of $37.13, indicating a potential downside of 53.44%. Given Moderna's stronger consensus rating and higher possible upside, analysts clearly believe Moderna is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Moderna's net margin of -143.55%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Moderna	-143.55%	-26.64%	-19.32%

Dr. Reddy's Laboratories has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81
Moderna	$1.94B	16.28	-$2.82B	-$8.15	N/A

Summary

Moderna beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Roivant Sciences had 19 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 21 mentions for Roivant Sciences and 2 mentions for Dr. Reddy's Laboratories. Roivant Sciences' average media sentiment score of 0.74 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	12 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential downside of 4.38%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Roivant Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,059.07	-$299.77M	-$0.60	N/A
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Roivant Sciences' net margin of -3,629.19%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Roivant Sciences beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDY vs. The Competition

Export

Metric	Dr. Reddy's Laboratories	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$12.01B	$6.19B	$6.95B	$23.51B
Dividend Yield	0.49%	0.64%	2.67%	4.04%
P/E Ratio	24.81	8.95	27.73	31.28
Price / Sales	3.35	24.94	535.76	20.85
Price / Cash	17.11	8.79	47.99	25.08
Price / Book	2.96	4.40	10.91	4.81
Net Income	$456M	$99.67M	$3.57B	$1.07B
7 Day Performance	-5.63%	3.03%	3.65%	1.74%
1 Month Performance	10.55%	9.68%	4.46%	2.76%
1 Year Performance	-3.24%	130.76%	35.83%	19.96%

Dr. Reddy's Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDY Dr. Reddy's Laboratories	1.5722 of 5 stars	$14.39 +2.8%	N/A	-6.0%	$12.01B	$3.58B	24.81	27,527
RVMD Revolution Medicines	1.7044 of 5 stars	$187.52 +0.0%	$134.50 -28.3%	+408.3%	$39.79B	$11.58M	N/A	250	Analyst Forecast Insider Trade
TEVA Teva Pharmaceutical Industries	4.7232 of 5 stars	$34.67 +3.7%	$41.78 +20.5%	+101.2%	$39.77B	$17.35B	26.00	33,950
ONC BeOne Medicines	4.7745 of 5 stars	$295.41 +1.6%	$390.00 +32.0%	+18.6%	$32.52B	$5.34B	66.30	12,000	Analyst Forecast
MRNA Moderna	1.1126 of 5 stars	$78.51 +8.3%	$37.13 -52.7%	+152.7%	$30.78B	$1.94B	N/A	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Summary

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Summary

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Summary

How does Dr. Reddy's Laboratories compare to Moderna?

Summary

How does Dr. Reddy's Laboratories compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Does the media prefer RVMD or RDY?

Which has more risk and volatility, RVMD or RDY?

Is RVMD or RDY more profitable?

Do analysts prefer RVMD or RDY?

Do institutionals & insiders have more ownership in RVMD or RDY?

Which has higher earnings & valuation, RVMD or RDY?

Summary

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Is TEVA or RDY a better dividend stock?

Which has more volatility and risk, TEVA or RDY?

Does the media refer more to TEVA or RDY?

Do institutionals and insiders hold more shares of TEVA or RDY?

Is TEVA or RDY more profitable?

Do analysts recommend TEVA or RDY?

Which has preferable valuation & earnings, TEVA or RDY?

Summary

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Do institutionals & insiders have more ownership in RDY or ONC?

Is RDY or ONC more profitable?

Which has higher valuation and earnings, RDY or ONC?

Which has more volatility and risk, RDY or ONC?

Do analysts recommend RDY or ONC?

Does the media favor RDY or ONC?

Summary

How does Dr. Reddy's Laboratories compare to Moderna?

Do institutionals & insiders believe in RDY or MRNA?

Which has more risk and volatility, RDY or MRNA?

Does the media favor RDY or MRNA?

Do analysts prefer RDY or MRNA?

Is RDY or MRNA more profitable?

Which has better earnings & valuation, RDY or MRNA?

Summary

How does Dr. Reddy's Laboratories compare to Roivant Sciences?

Does the media refer more to ROIV or RDY?

Do analysts recommend ROIV or RDY?

Which has more risk & volatility, ROIV or RDY?

Do insiders & institutionals believe in ROIV or RDY?

Which has better earnings and valuation, ROIV or RDY?

Is ROIV or RDY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools